Aktuellt
SENASTE
Redeye comments on Fluoguide announcing lung cancer as the next indication for FG001. Today’s announcement is in line with our estimations and, as such, does not come as a surprise. Nevertheless, we are encouraged by Fluoguide delivering on its planned clinical pipeline broadening, crucial to our investment thesis.
LÄS MER
